← Back to Treatments
🏅 FDA Orphan Designation

Ruconest

C1 ESTERASE INHIBITOR RECOMBINANT

Manufacturer: Pharming Healthcare Inc.

Indicated for:
Hereditary angioedema

FDA-Approved Indications (1)

indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE)

Population: adult and adolescent patients

Indications & Usage

1 INDICATIONS AND USAGE RUCONEST is a C1 esterase inhibitor [recombinant] indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Limitation of Use: Effectiveness was not established in HAE patients with laryngeal attacks. RUCONEST is a C1 esterase inhibitor [recombinant] indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). ( 1 ) Limitation of Use: Effectiveness was not established in HAE patients with laryngeal attacks.

💙 Support Programs

View all →
Ruconest
Pharming Healthcare Inc.

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.